key: cord-0795303-jbs71qfa
authors: Kline, E. C.; Panpradist, N.; Hull, I. T.; Wang, Q.; Oreskovic, A. K.; Han, P. D.; Starita, L. M.; Lutz, B. R.
title: Multiplex Target-Redundant RT-LAMP for Robust Detection of SARS-CoV-2 Using Fluorescent Universal Displacement Probes
date: 2021-08-23
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2021.08.13.21261995
sha: 794a95ff1609867ce96a29ff30353c94bbf4f117
doc_id: 795303
cord_uid: jbs71qfa

The increasing prevalence of variant lineages during the COVID-19 pandemic has the potential to disrupt molecular diagnostics due to mismatches between primers and variant templates. Point-of-care molecular diagnostics, which often lack the complete functionality of their high throughput laboratory counterparts, are particularly susceptible to this type of disruption, which can result in false negative results. To address this challenge, we have developed a robust Loop Mediated Isothermal Amplification assay with single tube multiplexed multi-target redundancy and an internal amplification control. A convenient and cost-effective target specific fluorescence detection system allows amplifications to be grouped by signal using adaptable probes for pooled reporting of SARS-COV-2 target amplifications or differentiation of the Internal Amplification Control. Over the course of the pandemic, primer coverage of viral lineages by the three redundant sub-assays has varied from assay to assay as they have diverged from the Wuhan-Hu-1 isolate sequence, but aggregate coverage has remained high for all variant sequences analyzed, with a minimum of 97.4% (Variant of Interest: Eta). In three instances (Delta, Gamma, Eta), a high frequency mismatch with one of the three sub-assays was observed, but overall coverage remained high due to multi-target redundancy. When challenged with extracted human samples the multiplexed assay showed 100% sensitivity for samples containing greater than 30 copies of viral RNA per reaction, and 100% specificity. These results are further evidence that conventional laboratory methodologies can be leveraged at the point-of-care for robust performance and diagnostic stability over time.

Introduction 3 4

The COVID-19 pandemic is an unprecedented crisis in the modern era, spreading across the 3 5 planet in a matter of months, infecting and killing millions, while disrupting the lives of billions (1). An 3 6 essential element of the response strategies to COVID-19 is diagnostic testing, which informs clinical 3 7

intervention, quarantine, and epidemiological monitoring (2). Nucleic acid amplification tests (NAATs) 3 8 remain the most accurate approach for diagnosis of infectious diseases including SARS-CoV-2 infection. 3 9

However, RNA viruses like SARS-CoV-2 have a high mutational rate, which can result in elevated levels 4 0 of sequence diversity accumulating as they propagate. This is a critical obstacle for NAATS because 4 1 mismatches between the primer oligonucleotides and the template sequences can impair an assay and 4 2 produce false negative results. As transmission has progressed, SARS-CoV-2 has diversified in distinct 4 3 lineages, each with signature mutations throughout the genome (3). The emergence of this genetic 4 4 diversity has rendered some NAATs susceptible to false negative results, causing these tests to be altered 4 5 or withdrawn by the U.S. FDA (4). This challenge posed by mutation for NAATs is not limited to SARS-4 6

CoV-2; similar phenomena have been observed for other human pathogens (5, 6). 4 7

Laboratory testing strategies to lessen this risk include redundant testing with alternative 4 8 methods, diagnostic panels with multiple target regions (7), and/or primer sets with degenerate bases to 4

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261995 doi: medRxiv preprint

Universal displacement probe design 9 9

Two engineered universal displacement probes (UDP) corresponding to the target adapter or IAC 1 0 0 adapter sequence were designed. Each UDP consists of an oligonucleotide duplex with a 3' overhang and 1 0 1 a fluorophore quencher pair (19).The adapter sequence is located at the 3' overhang position, with a 1 0 2 fluorophore spacer sequence at the 5' end and a 5' terminal fluorophore (6-FAM or TEX615). The 1 0 3 quencher (Iowa Black® FQ or Black hole Quencher®-2) sequence is a complementary fluorophore 1 0 4 spacer sequence and is labeled with a 3' dark quencher so that it quenches the fluorophore when annealed. 1 0 5

Probe adapters and universal displacement probe sequences were generated from randomized sequence 1 0 6

and manually modified in Geneious, using OligoAnalyzer and NUPACK as secondary analysis tools, to 1 0 7 minimize dimer and hairpin structures within and between the probes and adapted loop primers. All 1 0 8 designs were tested individually and multiplexed in combination against synthetic dsDNA gBlocks ™ 1 0 9

(Integrated DNA Technologies, Coralville, Iowa, USA) target and ssDNA IAC Ultramer ™ (Integrated 1 1 0 DNA Technologies, Coralville, Iowa, USA) fragments to inform iterative design changes to individual 1 1 1 assays. Final design iterations are reported; probes and quenchers oligonucleotides were sourced from 1 1 2

Interated DNA Technologies (Coralville, Iowa, USA). 1 1 3 Patient samples 1 1 4

A panel of 102 human respiratory specimens was used to evaluate our mLAMP assay 1 1 5

performance. These specimens collected from nasal or nasopharyngeal swabs were suspended in 3mL 1 1 6 viral transport medium (Becton Dickinson 220220), aliquoted, and stored at −80°C until testing as 1 1 7

described (20). The panel was originally characterized by OpenArray (ThermoFisher Scientific, Waltham, 1 1 8 MA, USA) to contain at least 30 COVID-POS across a wide range of concentrations and 30 COVID-1 1 9

negative samples as well as other samples identified as positive for other respiratory diseases including, 1 2 0

but not limited to, Streptococcus pneumoniae, Influenza, seasonal Coronavirus, Adenovirus, and 1 2 1

Enterovirus. Supplementary Table S1 shows detailed profile in each specimen used in this study. 1 2 2

Samples were reassessed in house for the presence of SARS-CoV-2 RNA, as described below, to account 1 2 3

for losses during freeze-thaws, storage, or extraction. In-house results were used as the reference standard. 1 2 4

Specimens were collected and tested for SARS-CoV-2 infection as part of the Seattle Flu Study, as 1 2 5 approved by the Institutional Review Board at the University of Washington (IRB#: STUDY0006181). 1 2 6

Informed consent was obtained for all participant samples, including for use of de-identified, remnant 1 2 7

specimens. 1 2 8 Patient sample preparation 1 2 9

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The RT-PCR protocol was prepared as previously described (20) coverage, collection on or before June 14, 2021 and submitted prior to July 1, 2021. The first 1000 1 6 0 sequence records for each VOC / VOI in the GISAID.ORG database were used for subsequent analysis. 1 6 1

This sequence library was screened for perfect identity matches with the primer binding regions of the 1 6 2 NC1, NC2, NC3 assays using the packages Biostrings (22) and Seqnir for R (23). 1 6 3

To efficiently combine mRT-LAMP assays and differentiate between target and IAC 1 6 5 amplification in a crude sample matrix requires two key features: a target specific probe technology ( Fig.  1  6  6 1) and a strand displacement polymerase with low non-template amplification. We developed fluorescent 1 6 7 universal displacement probes (UDPs) to allow multiplexed assays to be combined or parsed into 1 6 8 fluorescence channels with a minimum number of probes. UDPs themselves are engineered sequences 1 6 9 that use a universal adapter sequence on a loop primer for target-specific detection (Fig. 1A) . In the 1 7 0 configuration presented here, three independent SARS-CoV-2 targets are designed to report to a single 1 7 1 green (6-FAM) fluorescent probe, and the IAC is designed to report to a red (TEX615) fluorescence 1 7 2 channel (Fig. 1B) . We previously developed an in-house thermostable strand displacement polymerase 1 7 3

(TFpol) with very low nonspecific amplification that is amenable to multiplexing. The TFpol design was 1 7 4 inspired by the chimeric polymerase method of Morant (24) using the polI polymerase of Thermus 1 7 5

Thermophilus as the backbone, an enzyme shown to be tolerant of many polymerase inhibitors (25, 26). 1 7 6

UDPs and TFpol combine to allow for a flexible and robust mLAMP system, compatible with multiple 1 7 7 target redundancy, IAC controls, and potential for reduced sample preparation. Tolerance to transport media 2 2 0

To evaluate the tolerance of the assay to potential media contaminants, a selection of 2 2 1 commercially available co buffered transport reagents were spiked into reactions with a 25% final 2 2 2 concentration. For a 20µL total reaction volume, 5µL of 1x DMEM (11965-06, Gibco), 1x VTM (BD 2 2 3 220527, Copan), 1x PBS (SH30256.01, GE) or 0.9% sodium chloride (diluted from 5M stock 71386-1L, 2 2 4

Sigma) was added into the mRT-LAMP reactions with final synthetic SARS-CoV-2 RNA of 0, 20, or 200 2 2 5 copies (Supp. Fig. S2 ). Successful SARS-COV-2 amplification was observed for all samples containing 2 2 6 template under all buffer conditions. 2 2 7

Performance with extracted clinical specimens 2 2 8

The SARS-CoV-2 mRT-LAMP was evaluated against a collection of pre-extracted patient 2 2 9

specimens. Of the 102 samples evaluated by RT-PCR, 93 were determined to contain human origin 2 3 0 material by positive RNase P (RP) results; all samples that were negative for RP were also negative for 2 3 1 SARS-CoV-2 and were considered indeterminate. Of the 93 specimens verified to contain human 2 3 2 material, 60 were found to be negative for SARS-CoV-2, and 30 were found to be positive by both 2 3 3 reference RT-RCR assays. The three remaining samples were positive for SARS-CoV-2 by one reference 2 3 4

RT-PCR assay and negative by the second, resulting in an inconclusive classification. All samples that 2 3 5 were indeterminate or inconclusive by RT-PCR were excluded from analysis. Clinical samples were run 2 3 6 in duplicate mRT-LAMP reactions. 2 3 7

The mRT-LAMP was able to detect negatives with 100% specificity in both sets of replicates, 2 3 8 with detection of the IAC but no target signal (Fig. 3) . Conversely, sensitivity for the two replicates was 2 3 9 90% (27/30) and 87% (26/30), respectively. For samples found to have more than 30 copies / mRT-2 4 0 LAMP reaction by reference RT-PCR, sensitivity was improved to 100% (21/21) for both replicates. The were amplified by duplicate mRT-LAMP reactions. Detected mRT-LAMP signals for SARS-CoV-2 2 5 0 (CoV) are shown in blue, and IAC signals are shown in orange; replicate pairs are connected by a line 2 5 1 segment. Mean copy number was derived from qPCR results of N1, N1 PCR (see Supplemental Table  2 5 2 S1). 2 5 3 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.13.21261995 doi: medRxiv preprint Primer coverage analysis 2 5 4

Individual primer sets had variability in the frequency of perfect primer matches across the 2 5 5 VOC/VOI sequence libraries ( Table 2) . Presence of mismatches does not necessarily preclude assay 2 5 6 functionality and is therefore an underestimate of realized assay coverage. Combined primer coverage, 2 5 7

where one or more primer sets had a perfect match for the target, was high across all variants, with a 2 5 8 minimum 97.4% (for Eta). 2 5 9 

WHO Director-General's opening remarks at the media briefing on 3 4 7 COVID-19 -11

This initial validation of a multiplexed reverse transcription LAMP assay is a further step towards 2 6 5 more resilient point-of-care NAAT technologies with convenient implementation and development. The 2 6 6 assay supports robust but basic functionality with competitive sensitivity, speed, and a low complexity 2 6 7 fluorescence detection system. Because VTM has been shown to inhibit conventional PCR strategies (27), 2 6 8 we designed our assay to use our in-house chimeric polymerase, TFpol, which has been proven to be 2 6 9 effective with complex samples containing various transport media. TFpol supports multiplexed LAMP 2 7 0amplifications which have been infrequently demonstrated. These capabilities, taken together, enable 2 7 1 features that are contemporary in high-throughput laboratory testing but more challenging in point-of 2 7 2 care diagnostics. 2 7 3Multiplexed LAMP reactions with the ability to differentiate individual products by target 2 7 4 specific probes enable two key aspects of robust NAAT testing: internal amplification controls and 2 7 5 multiple target redundancy. IACs are widely accepted as a means of assuring the sample could detect a 2 7 6 positive result if the target result is negative, by verifying that the reaction chemistry was viable and not 2 7 7 inhibited by sample contaminants or otherwise compromised (28). In the context of LAMP amplification, 2 7 8 internal controls can impair successful target detection; the resource demands of a successful LAMP 2 7 9 mean co-amplification of multiple products with varying inputs often lead to the competitive inhibition of 2 8 0 slower assays or lower concentration of target (Fig. 2B, 2C) . Presumably, this can be attributed to 2 8 1 resource depletion of limiting reagents in the reaction mix. To address this resource competition, we 2 8 2 devised a shared-primer internal control strategy where the performance of the IAC has been intentionally 2 8 3 impaired by using a reduced primer set. The delayed time-to-detection of the IAC can then be further 2 8 4 controlled by adjusting the concentration of control template, ensuring reduced competition with the 2 8 5 target amplification. 2 8 6The single-pot multiple target redundancy is a defining feature of this assay design even with the 2 8 7 grouped reporter signal. Pathogen genetic variability is an important failure mode for nucleic acid 2 8 8 amplification tests; a single nucleotide point mutation (SNP) can result in underperformance of a LAMP 2 8 9(29) or PCR reaction (30). As the COVID-19 pandemic progresses, the virus will continue to accumulate 2 9 0 mutations and diversify, posing a challenge to NAATs used for diagnosis. An alignment of publicly 2 9 1 available SARS-CoV-2 genomes at the time of writing reveals multiple genomes with known mutations 2 9 2 in the primer footprints of the CDC PCR designs and a range of other published assays, suggesting that 2 9 3 mutations are an existential problem (data not shown). The likelihood of these mutations rendering all 2 9 4 three target amplifications ineffective simultaneously is lower than for a single assay. This principle is 2 9 5 often incorporated in commercially available conventional laboratory based NAATs so this capability 2 9 6represents a convergence of state-of-the-art diagnostic methods and POC diagnostic capabilities. Our own 2 9 7 analysis ( Fig. 2) found that, since the design of the multiplex assay in early 2020 against the NCBI 2 9 8 reference sequence, the emergence of the many variant lineages had resulted in some high frequency 2 9 9 mismatches in primer binding regions of our targets. While many single nucleotide polymorphisms are 3 0 0 likely to be tolerated by a LAMP reaction, some mutations, such as those located at or near the critical 3 0 1 termini of primers, may interfere with diagnostic performance (31). Variants Delta, Gamma and Eta each 3 0 2 had fixed, or almost fixed allele mutations in primer sets NC3, NC1, and NC2 respectively. When 3 0 3 considered in combination as a multiplex assay, the primers still showed good overall coverage despite 3 0 4 one of the three assays being potentially compromised; this is a clear demonstration of the value that 3 0 5 multitarget redundancy holds for viral diagnostics. In the case of the Delta variant, which currently has 3 0 6 rising incidence (32), a sequence mutation within the NC3 primer set was identified on the reverse 3 0 7bumper primer (B3, data not shown). This primer could be altered to be inclusive to the delta variant or 3 0 8 redesigned without disruption to the diagnostic, ensuring no lapse in diagnostic coverage over time. 3 0 9In order to fully realize a field ready POC assay additional development is planned. While 3 1 0 preliminary testing suggests that the system is tolerant to inhibitors that might typically interfere with a 3 1 1 direct-to-amplification workflow, in-amplification sample lysis, and testing with human sample matrix 3 1 2 will be necessary. This is particularly important for understanding the role of RNAses on assay 3 1 3sensitivity. With the current ssDNA IAC design RNA integrity is not assessed by the control system, 3 1 4 which is essential for a fully functional process control. Future iterations will address this by 3 1 5implementing an encapsidated RNA, such as MS2 coliphage for this purpose. Sampling, storage, and 3 1 6 portable device solutions are already under development (13). These advancements will allow us to 3 1 7 eschew infrastructure requirements that have acted as a bottleneck in current testing efforts, and when 3 1 8 combined with the robust multiplex chemistry presented here, could act as a practical solution for 3 1 9 decentralized testing. used in this study and characterized these specimens using RT-qPCR and OpenArray. B.R.L. oversaw the 3 2 6 study. All authors contributed to writing this manuscript. 3 2 7 Acknowledgments 3 2 8We thank other project members in the Lutz lab for their feedback: Robert Atkinson, Michael 3 2 9Roller, Crissa Bennett, Daniel Lyon, and Jack Henry Kotnik. We thank Dr. Syamal Raychaudhuri, Dr.